A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors

NCT04865315 | Recruiting

• 1 other identifier: HiLoGlio Organoid Study
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

There is a high medical need to improve treatment outcome for high-grade and low-grade glioma since no curative treatment is available. To achieve this goal, a broader understanding is needed of the causes of inter-and intratumoral heterogeneity; glioma dedifferentiation and invasion; the major determinants of malignancy and treatment failure in glioma patients. Patient-derived organoid (PDOs) of high-grade gliomas and low-grade gliomas will be used to identify the mechanisms that underlie this malignant behaviour and treatment resistance. This insight may be used to develop patient avatars to simultaneously test multiple new treatment modalities that are predictive for survival and quality of life of glioma patients.

Conditions

Low-grade Glioma; High Grade Glioma

Keywords

Prospective study; Patient-derived organoids

Outcome Measures

Primary Outcomes (1)

• Phenotypic, genetic, epigenetic proteomic and transcriptomic profile of the LGG/HGG PDOs

  Phenotypic, genetic, epigenetic proteomic and transcriptomic profile of the LGG/HGG PDOs will be performed after establishing PDO and the data will be compared with the phenotypic, genetic, epigenetic, proteomic and transcriptomic profile of the parental tumor. DNA isolated from peripheral blood will be used as normal reference DNA for (epi)genetic profiling.

  Baseline tumor resection and blood sampling

Study Arms (2)

Low grade glioma patients

Patients who have a MRI lesion suspected for a low grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor

High grade glioma patients

Patients who have a MRI lesion suspected for a high grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who have an MRI lesion suspected for a low- or high grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor.

You may qualify if:

• MRI diagnosis of low grade glioma (LGG) or high grade glioma (HGG)
• Age 18 years or older
• Patient is eligible for a resection of the tumor

You may not qualify if:

• Contra-inidication for neurosurgical resection of the tumor.
• Incapacitated patient, unable to give informed consent.

Sponsors & Collaborators

• Maastricht Radiation Oncology: lead
• Maastricht University Medical Center: collaborator
• Zuyderland Medisch Centrum: collaborator
• Ziekenhuis Oost-Limburg: collaborator

Study Sites (1)

Maastricht Radiation Oncology

Maastricht, Limburg, 6229ET, Netherlands

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Tumor tissue, blood

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Officials

• Marc Vooijs, Prof. Dr.

  Maastro Radiaton Oncology clinic

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Annika Noordink, Msc

CONTACT

+31(0)884456010; annika.noordink@maastro.nl

Chantal Overhof

CONTACT

+31(0)884455686; chantal.overhof@maastro.nl

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 26, 2021
• First Posted: April 29, 2021
• Study Start: May 1, 2022
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: January 27, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

NL (1)